SUPERNUS PHARMACEUTICALS INC
CNS disease therapeutics and pharmaceutical compounds
New patent ·
- Sector
- Biotech
- Headquarters
- ROCKVILLE, MD
- Latest Form D
- $15M, Feb 2011
- Total capital
- $15M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $15M
- 1 Form D · last Feb 2011
- 189 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 5
- 20 pending · first 2024
- Rank in peer group#269 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$15M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#269 · top 19%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Charles W. Newhall, IIIDirectorNamed in SEC Form D filings
- Frederick M. HudsonDirectorNamed in SEC Form D filings
- Jack A. KhattarExecutive Officer, DirectorNamed in SEC Form D filings
- John M. SiebertDirectorNamed in SEC Form D filings
- Jones W. Bryan, Ph.D.Executive OfficerNamed in SEC Form D filings
- M. James Barrett, Ph.D.DirectorNamed in SEC Form D filings
Show all 13 people
- Michael James BighamDirectorNamed in SEC Form D filings
- Michael B. Sheffery, Ph.D.DirectorNamed in SEC Form D filings
- Padmanabh P. Bhatt, Ph.D.Executive OfficerNamed in SEC Form D filings
- Paolo P. Baroldi, M.D., Ph.D.Executive OfficerNamed in SEC Form D filings
- Russell P. WilsonExecutive OfficerNamed in SEC Form D filings
- Tami T. Martin, R.N., Esq.Executive OfficerNamed in SEC Form D filings
- William A. NuergeDirectorNamed in SEC Form D filings
What it has protected
USPTO · 5 granted of 25- New patentDerivatives Of Substituted Morpholines And Uses ThereofUSPTOUS 12,747,218
- PendingProcess Of Making Derivatives Of Substituted MorpholinesUSPTOApplication 19400185
- GrantedMethod Of Treatment Of Cns DisordersUSPTOUS 12,569,471
Show all 25 patent records
- Derivatives Of Substituted Morpholines And Uses ThereofSep 29, 2026 · US 12,747,218Granted
- Process Of Making Derivatives Of Substituted MorpholinesMar 19, 2026 · Application 19400185Pending
- Method Of Treatment Of Cns DisordersMar 10, 2026 · US 12,569,471Granted
- Substituted Derivatives Of IsoindolesJan 29, 2026 · Application 18784106Pending
- Methods For Producing Viloxazine Salts And Novel Polymorphs ThereofJan 8, 2026 · Application 19328907Pending
- Formulations Of ViloxazineDec 4, 2025 · Application 19306464Pending
- Substituted Derivatives Of IsoindolesOct 28, 2025 · US 12,454,535Granted
- Formulations Of ViloxazineJul 17, 2025 · Application 19171852Pending
- Method Of Treatment Of Attention Deficit/hyperactivity Disorder (adhd)Jul 17, 2025 · Application 19171862Pending
- Formulations Of ViloxazineJul 10, 2025 · Application 19093755Pending
- Formulations Of MazindolMay 22, 2025 · Application 19018355Pending
- Derivatives Of Substituted Morpholines And Uses ThereofApr 17, 2025 · Application 18999866Pending
- Substituted Derivatives Of Isoindoles And Uses ThereofApr 3, 2025 · Application 18899299Pending
- Derivatives Of Substituted Morpholines And Uses ThereofFeb 4, 2025 · US 12,215,097Granted
- Method Of Treatment Of Attention Deficit/hyperactivity Disorder (adhd)Jan 9, 2025 · Application 18891542Pending
- Derivatives Of Substituted Morpholines And Uses ThereofOct 17, 2024 · Application 18740059Pending
- Derivatives Of Substituted Morpholines And Uses ThereofOct 10, 2024 · Application 18617255Pending
- Process Of Making Derivatives Of Substituted MorpholinesApr 23, 2024 · US 11,964,951Granted
- Formulations Of ViloxazineNov 30, 2023 · Application 18232716Pending
- Derivatives Of Substituted Morpholines And Uses ThereofApplication PCTUS2024021473Pending
- Substituted Derivatives Of Isoindoles And Uses ThereofApplication 63683074Pending
- Substituted Derivatives Of IsoindolesApplication PCTUS2024039574Pending
- Substituted Derivatives Of Isoindoles And Uses ThereofApplication PCTUS2024048748Pending
- Substituted Derivatives Of Isoindoles And Uses ThereofApplication 63541465Pending
- Substituted Derivatives Of IsoindolesApplication 63529077Pending
Related companies, and why
- OtonomySimilar federal contract value in Biotech · null in contracts
- Endlyz Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Avilar TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Siolta Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- PEPTIDE LOGIC LLCSimilar federal contract value in Biotech · null in contracts
- Biomea Fusion, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .